Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03993535 · ClinicalTrials.gov registry record · Phase 4
Predicting Treatment Response in Patients With OCD
A Phase 4 study of Obsessive - Compulsive Disorder, sponsored by University of Sao Paulo.
- Completed
- Registry status
- Phase 4
- Development phase
- 250
- Enrollment target
- 4
- Study locations
NCT03993535 is a Phase 4 study of Obsessive - Compulsive Disorder that has completed, run by University of Sao Paulo. The registered enrollment target is 250 participants, below the 2,062-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT03993535, a Phase 4 study of Obsessive - Compulsive Disorder, has completed, sponsored by University of Sao Paulo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 250 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study consists of a naturalistic follow-up of subjects with Obsessive-Compulsive Disorder (OCD) that have participated in a global study investigating brain signatures of OCD funded by the National Institutes of Mental Health (RO1MH113250), with the following participant sites: the US (Columbia University, PI: Helen Blair Simpson), Brazil (University of Sao Paulo, PIs: Euripedes Miguel and Roseli G Shavitt), India (National Institutes of Mental Health, PI: Janardhan Reddy), The Netherlands (VU Amsterdam Medical Center, PI: Odile van den Heuvel), and South Africa (University of Cape Town, PI: Dan Stein; Stellenbosch University, PI: Christine Lochner). In this cross-sectional study, two-hundred and fifty unmedicated subjects with OCD (50 per site) will be assessed for clinical, neurocognitive and neuroimaging data. After completion of this study, participants willing to receive evidence-based treatments for OCD will be treated with the available resources in each site and will be assessed for treatment response status periodically, with a final assessment after 1 year of naturalistic follow-up. At this point, we will investigate baseline clinical, neurocognitive and neuroimaging variables associated with the treatment response status.
Conditions Studied
Interventions
- DRUG selective serotonin reuptake inhibitor
Study Locations (4)
Other
- Institute of Psychiatry - Hospital of Clinics - University of São Paulo - São Paulo
- OCD Clinic, Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS) - Bangalore
- Faculty of Medicine and Health Sciences, Department of Psychiatry, Stellenbosch University - Cape Town
New York
- Center for OCD and Related Disorders, New York State Psychiatric Institute/Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2018-10-10 |
| Est. Completion | 2023-04-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03993535
The ClinicalTrials.gov registry entry for NCT03993535 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,062-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (88% lower). The listed sponsor is University of Sao Paulo, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 1 intervention - of which selective serotonin reuptake inhibitor is the first listed.
NCT03993535 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, New York.
Frequently Asked Questions
What is clinical trial NCT03993535 about?
NCT03993535 is a clinical study titled "Predicting Treatment Response in Patients With OCD". This study consists of a naturalistic follow-up of subjects with Obsessive-Compulsive Disorder (OCD) that have participated in a global study investigating brain signatures of OCD funded by the National Institutes of Mental Health (RO1MH113250), with the following participant sites: the US (Columbia...
What is the current status of trial NCT03993535?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2018-10-10. Estimated completion is 2023-04-30.
What conditions does trial NCT03993535 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT03993535?
The interventions under investigation include: selective serotonin reuptake inhibitor (DRUG).
Who is sponsoring clinical trial NCT03993535?
This trial is sponsored by University of Sao Paulo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03993535 being conducted?
This trial has 4 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder
ACTIVE NOT RECRUITING · Phase 4
-
Treatment of Obsessive-Compulsive Disorder
COMPLETED · Phase 4
-
Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)
COMPLETED · Phase 4
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
-
Mechanisms of Exposure Therapy for OCD
RECRUITING · NA
-
Using Personalized Assessments in the Treatment of Childhood OCD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.